BioNTech (NASDAQ:BNTX) Trading Down 0.7% - Here's Why

BioNTech SE (NASDAQ:BNTX - Get Free Report) shares dropped 0.7% on Tuesday . The stock traded as low as $119.20 and last traded at $120.82. Approximately 538,537 shares were traded during trading, a decline of 34% from the average daily volume of 811,532 shares. The stock had previously closed at $121.72.

Analyst Ratings Changes

BNTX has been the subject of a number of research analyst reports. BMO Capital Markets reaffirmed an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft lifted their price objective on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, September 19th. TD Cowen lowered their target price on BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a report on Tuesday, November 5th. Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research report on Tuesday, November 26th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $138.67.

BioNTech Stock Performance

The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm's fifty day moving average price is $113.95 and its two-hundred day moving average price is $99.75. The stock has a market capitalization of $28.97 billion, a PE ratio of -57.53 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period last year, the company earned $0.73 earnings per share. BioNTech's quarterly revenue was up 38.9% compared to the same quarter last year. As a group, equities research analysts forecast that BioNTech SE will post -3.72 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently made changes to their positions in BNTX. Planning Capital Management Corp raised its position in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after buying an additional 450 shares during the period. Blue Trust Inc. raised its position in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after purchasing an additional 388 shares during the period. GAMMA Investing LLC lifted its stake in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after purchasing an additional 111 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock worth $155,000 after purchasing an additional 1,562 shares during the period. Finally, Caprock Group LLC acquired a new stake in shares of BioNTech during the 2nd quarter worth about $206,000. Institutional investors and hedge funds own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.